Furthermore, treatment with the TβRII agonist TGF‐β1 rescued the reduced expression of TβRII and p‐Smad3 as well as the migration ability of breast cancer cells mediated by HTR1A overexpression. This evidence concerns the gene SMAD3 and breast cancer.